| 董校良,王象征,王 捷,方 炜,宫扣飞.甲状腺乳头状癌组织SMYD2、GRK6表达与临床病理特征、增殖基因和预后的关系分析[J].,2021,(24):4699-4704 |
| 甲状腺乳头状癌组织SMYD2、GRK6表达与临床病理特征、增殖基因和预后的关系分析 |
| Analysis of the Relationship between SMYD2 and GRK6 Expression and Clinicopathological Features, Proliferation Genes and Prognosis in Papillary Thyroid Carcinoma |
| 投稿时间：2021-04-23 修订日期：2021-05-17 |
| DOI：10.13241/j.cnki.pmb.2021.24.020 |
| 中文关键词: 甲状腺乳头状癌 SMYD2 GRK6 临床病理特征 增殖基因 预后 |
| 英文关键词: Papillary thyroid carcinoma SMYD2 GRK6 Clinicopathological Features Proliferation genes Prognosis |
| 基金项目:江苏省南京市医学科技发展项目（YKK15159）；江苏省自然科学基金项目（BK201602307） |
|
| 摘要点击次数: 642 |
| 全文下载次数: 315 |
| 中文摘要: |
| 摘要 目的：探讨甲状腺乳头状癌组织中SET和MYND域蛋白2（SMYD2）、G蛋白偶联受体激酶6（GRK6）表达与临床病理特征、增殖基因和预后的关系。方法：选择2015年1月至2017年12月期间我院收治的83例甲状腺乳头状癌患者，取甲状腺乳头状癌患者手术切除的癌组织及癌旁组织（距肿瘤组织边缘≥5 cm）标本，采用qRT-PCR检测SMYD2、GRK6以及增殖基因[叉头盒蛋白A1（FOXA1）、程序性细胞死亡基因4（PDCD4）、Xklp2靶蛋白(TPX2)]表达。分析SMYD2、GRK6表达与临床病理特征、增殖基因和预后的关系。分析甲状腺乳头状癌患者预后的影响因素。结果：癌组织SMYD2、GRK6、FOXA1、PDCD4、TPX2表达高于癌旁组织（P＜0.05）。Pearson相关性分析显示：SMYD2、GRK6表达与FOXA1、PDCD4、TPX2表达呈正相关（P＜0.05）。肿瘤直径＞1 cm、低中度分化、T3～T4a期、N1a～N1b期患者癌组织中SMYD2、GRK6表达高于肿瘤直径≤1 cm、高度分化、T1～T2期、N0期患者（P＜0.05）。SMYD2、GRK6高表达组患者3年无进展生存期（PFS）、总生存期（OS）生存率低于SMYD2、GRK6低表达组（P＜0.05）。Cox比例风险模型分析结果显示N1a～N1b期、SMYD2≥2.95、GRK6≥3.02是甲状腺乳头状癌患者不良预后的危险因素（P＜0.05）。结论：甲状腺乳头状癌组织中SMYD2、GRK6表达增高，SMYD2、GRK6过表达与癌细胞增殖、侵袭和术后预后不良有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between the SET and MYND domain-containing protein 2 (SMYD2), G-protein coupled receptor kinase 6 (GRK6) expression and clinicopathological features, proliferation genes and prognosis in papillary thyroid carcinoma tissues. Methods: A total of 83 patients with papillary thyroid carcinoma who were admitted to our hospital from January 2015 to December 2017 were selected. Surgically resected cancer tissues and paracancerous tissues (≥5 cm from the tumor tissue margin) of patients with papillary thyroid carcinoma were collected. The expression of SMYD2, GRK6 and proliferating proteins [forkhead box protein A1 (FOXA1), programmed cell death gene 4 (PDCD4), and target protein Xklp2 (TPX2)] were detected by qRT-PCR. The relationship between the expression of SMYD2 and GRK6 and clinicopathological features, proliferative proteins and prognosis were analyzed. The prognostic factors of patients with papillary thyroid carcinoma were analyzed. Results: The expression of SMYD2, GRK6, FOXA1, PDCD4 and TPX2 in cancer tissues were higher than those in paracancerous tissues(P<0.05). Pearson correlation analysis showed that the expression of SMYD2 and GRK6 were positively correlated with the expression of FOXA1, PDCD4 and TPX2 (P<0.05). The expression of SMYD2 and GRK6 in cancer tissues of patients with tumor diameter > 1 cm, low and moderately differentiated, T3～T4a stage and N1a～N1b stage were higher than those of patients with tumor diameter ≤1 cm, highly differentiated, T1～T2 stage and N0 stage (P<0.05). The 3-year progression-free survival (PFS) and overall survival (OS) of patients with high SMYD2 and GRK6 expression groups were lower than those with low SMYD2 and GRK6 expression groups(P<0.05). Cox proportional risk model analysis showed that N1a～N1b stage, SMYD2 ≥2.95 and GRK6≥3.02 were risk factors for poor prognosis in patients with papillary thyroid carcinoma (P<0.05). Conclusion: The expression of SMYD2 and GRK6 in papillary thyroid carcinoma tissues are increased, and the overexpression of SMYD2 and GRK6 are related to the proliferation, invasion and poor postoperative prognosis of cancer cells. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
